Amgen Inc. Faces Risks with Obesity Drug, Causing Stock to Slip
Published on November 12, 2024
Amgen Inc. (NASDAQ: AMGN) recently faced a setback as safety concerns emerged regarding their obesity candidate drug. This update caused the company's stock to slip. Investment firm Cantor has cited these concerns, raising questions about the safety profile of the drug. However, Amgen's problems go beyond this issue, as their weak profit performance has also impacted their stock value. Investors are urged to seek professional advice from Stocks Prognosis to make informed decisions on the future movement of Amgen's stock.
Investor opinions & comments
To leave a comment, you need to Login or Register.
EmilyMiller
November 16, 2024 at 06:19
I'm interested to see how this setback will impact Amgen's future plans and drug development
RiskyRachel
November 14, 2024 at 23:39
I'm not sure if Amgen can overcome these safety concerns. It could have a long-lasting impact on their reputation
JohnSmith
November 14, 2024 at 19:07
What are the specific safety concerns raised by Cantor? I wonder if Amgen has a plan to address these issues
InvestorIvy
November 14, 2024 at 18:49
Given Amgen's weak profit performance, are they a risky investment? I'm not convinced they can turn things around
InvestmentIvy
November 13, 2024 at 14:05
I am curious about the safety concerns surrounding Amgen's obesity drug. I hope they can address these issues quickly